Study of an experimental drug plus immunotherapy for advanced solid tumors
Treatments studied
Part of Cancer, Digestive system, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new drug called GV20-0251 combined with an immunotherapy (anti-PD-1) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old.
- You have an advanced solid tumor (like certain types of lung, breast, colon, or liver cancer) that has not improved with standard treatment, or you cannot tolerate standard treatment.
- You have had no more than 2 prior treatments for your cancer (unless you have melanoma and have not had prior treatment).
- You have at least one measurable tumor that can be seen on scans.
- You have had a blood test and are in generally good health (able to do daily activities).
- If you are of childbearing age, you agree to use birth control during the study and for 4 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, GV20-0251, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and helpful.
This trial tests a new drug called MGC026 that targets a protein called B7-H3 on cancer cells, aiming to shrink or slow different advanced solid tumors. It is an early-phase study to find the right dose and check safety.
This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.
This trial tests a new medicine, PF-08046876, for people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. It aims to see if the drug is safe and works against these cancers.
This trial tests a new study drug, GV20-0251, for people with advanced solid tumors that no longer respond to standard therapies. It aims to see if the drug can shrink tumors or slow their growth.
This early-phase study tests GV20-0251 (an anti-cancer treatment) by itself and combined with pembrolizumab, to see how well it works and how safe it is. It is for adults with advanced solid tumors that have grown despite standard treatments, or where standard treatments aren’t an option.
Hear when a new Uterine Cervical Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.